← Leaderboards
Celia A. Schiffer
Univ Of Massachusetts Med Sch Worcester
$33,871,325
Attributed
$36,182,033
Total exposure
20
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.3M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$63,854,215 · 23
By mechanism
P01$36,548,745 · 6
R01$20,217,002 · 7
P30$3,289,168 · 1
R21$1,378,422 · 3
R35$1,005,000 · 1
R56$752,745 · 1
Top collaborators
- Lisa A. Cavacini4 shared
- Katherine A Fitzgerald4 shared
- Yang Wang2 shared
- James B Munro1 shared
Most similar at Univ Of Massachusetts Med Sch Worcester
Same institution · by research overlap
- Leslie J. Berg$20,585,080
- Eric S Huseby$7,301,178
- Mario Stevenson$40,259,093
- Brian Woody Sherman$2,344,609
- Sarah N Zvornicanin$108,064
Others in their field
Top investigators on “Structure”
- David Heimbrook · Leidos Biomedical Research, Inc.$475,333,582
- Barton F Haynes · Duke University$444,977,767
- Lawrence Corey · Fred Hutchinson Cancer Center$334,646,086
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$315,257,203
Research focus
StructureComplexViralDrug ResistanceEnzymesVariantMutationActive SitesMolecularSiteDrug DesignDesignVirusProtease InhibitorHiv-1BasePharmaceutical PreparationsInhibitor/AntagonistEquilibriumPeptide HydrolasesResistanceEvolutionEventAffinity
Grant awards (100)
Structure-guided and epitope-based design of potent and broadly neutralizing nanobodies for COVID-19 mucosal immunotherapy$677,986
R01 · FY2025 · AI
Defining and Avoiding Molecular Mechanisms of Drug Resistance$502,500
R35 · FY2025 · GM · contact PI
Dynamics and Evolution of HIV Gag and GagPol processing$752,745
R56 · FY2024 · AI
Structurally dissecting APOBEC3's for HIV-1 restriction and beyond$638,187
R01 · FY2024 · AI · contact PI
Defining and Avoiding Molecular Mechanisms of Drug Resistance$502,500
R35 · FY2024 · GM · contact PI
Structure-guided and epitope-based design of potent and broadly neutralizing nanobodies for COVID-19 mucosal immunotherapy$694,551
R01 · FY2023 · AI
Structurally dissecting APOBEC3's for HIV-1 restriction and beyond$650,818
R01 · FY2023 · AI · contact PI
Integration of Evolution to Avoid Resistance in Structure Based Drug Design$580,386
R01 · FY2023 · GM · contact PI
Structure-guided and epitope-based design of potent and broadly neutralizing nanobodies for COVID-19 mucosal immunotherapy$694,299
R01 · FY2022 · AI
Structurally dissecting APOBEC3's for HIV-1 restriction and beyond$663,123
R01 · FY2022 · AI · contact PI
Integration of Evolution to Avoid Resistance in Structure Based Drug Design$590,475
R01 · FY2022 · GM · contact PI
Structurally dissecting APOBEC3's for HIV-1 restriction and beyond$674,415
R01 · FY2021 · AI · contact PI
Structure-guided and epitope-based design of potent and broadly neutralizing nanobodies for COVID-19 mucosal immunotherapy$664,782
R01 · FY2021 · AI
Integration of Evolution to Avoid Resistance in Structure Based Drug Design$599,223
R01 · FY2021 · GM · contact PI
Design of Protease Inhibitors to Target HTLV-1$251,250
R21 · FY2021 · AI · contact PI
Integration of Evolution to Avoid Resistance in Structure Based Drug Design$67,000
R01 · FY2021 · GM · contact PI
Structurally dissecting APOBEC3's for HIV-1 restriction and beyond$702,264
R01 · FY2020 · AI · contact PI
Integration of Evolution to Avoid Resistance in Structure Based Drug Design$659,437
R01 · FY2020 · GM · contact PI
Design of Protease Inhibitors to Target HTLV-1$209,375
R21 · FY2020 · AI · contact PI
Drug Resistance in HCV NS3/4A - Inhibitor binding versus substrate recognition$588,464
R01 · FY2019 · AI · contact PI
Structurally dissecting APOBEC3's for HIV-1 restriction$582,430
R01 · FY2019 · AI · contact PI
The Interdependency of Drug Resistance Evolution and Drug Design: HIV-1 Protease$1,560,549
P01 · FY2018 · GM · contact PI
The structural & dynamic basis for the interdependence of drug resistance$735,976
P01 · FY2018 · GM · contact PI
Drug Resistance in HCV NS3/4A - Inhibitor binding versus substrate recognition$588,464
R01 · FY2018 · AI · contact PI
Structurally dissecting APOBEC3's for HIV-1 restriction$587,553
R01 · FY2018 · GM · contact PI
Structurally dissecting APOBEC3's for HIV-1 restriction$28,950
R01 · FY2018 · GM · contact PI
Administrative Core$22,412
P01 · FY2018 · GM · contact PI
The Interdependency of Drug Resistance Evolution and Drug Design: HIV-1 Protease$1,560,549
P01 · FY2017 · GM · contact PI
The structural & dynamic basis for the interdependence of drug resistance$735,976
P01 · FY2017 · GM · contact PI
Structurally dissecting APOBEC3's for HIV-1 restriction$592,524
R01 · FY2017 · GM · contact PI
Drug Resistance in HCV NS3/4A - Inhibitor binding versus substrate recognition$588,464
R01 · FY2017 · AI · contact PI
Administrative Core$22,412
P01 · FY2017 · GM · contact PI
The Interdependency of Drug Resistance Evolution and Drug Design: HIV-1 Protease$1,560,549
P01 · FY2016 · GM · contact PI
The structural & dynamic basis for the interdependence of drug resistance$735,976
P01 · FY2016 · GM · contact PI
Structurally dissecting APOBEC3's for HIV-1 restriction$614,226
R01 · FY2016 · GM · contact PI
Drug Resistance in HCV NS3/4A - Inhibitor binding versus substrate recognition$523,252
R01 · FY2016 · AI · contact PI
The Interdependency of Drug Resistance Evolution and Drug Design: HIV-1 Protease$89,751
P01 · FY2016 · GM · contact PI
Administrative Core$22,412
P01 · FY2016 · GM · contact PI
The Interdependency of Drug Resistance Evolution and Drug Design: HIV-1 Protease$1,560,549
P01 · FY2015 · GM · contact PI
The structural & dynamic basis for the interdependence of drug resistance$735,976
P01 · FY2015 · GM · contact PI
Structural Characterization of APOBECS's Atomic interactions$339,919
P01 · FY2015 · GM · contact PI
Drug Resistance in HCV NS3/4A - Inhibitor binding versus substrate recognition$262,627
R01 · FY2015 · AI · contact PI
Administrative Core$22,412
P01 · FY2015 · GM · contact PI
The Interdependency of Drug Resistance Evolution and Drug Design: HIV-1 Protease$1,710,847
P01 · FY2014 · GM · contact PI
The structural & dynamic basis for the interdependence of drug resistance$811,049
P01 · FY2014 · GM · contact PI
Drug Resistance in HCV NS3/4A - Inhibitor binding versus substrate recognition$407,138
R01 · FY2014 · AI · contact PI
Structural Characterization of APOBECS's Atomic interactions$352,319
P01 · FY2014 · GM · contact PI
Administrative Core$22,412
P01 · FY2014 · GM · contact PI
Structural Characterization of APOBECS's Atomic interactions$421,575
P01 · FY2013 · GM · contact PI
Elucidating the Interplay of Protease Substrate Recognition and Drug Resistance$384,429
R01 · FY2013 · GM · contact PI
Drug Resistance in HCV NS3/4A - Inhibitor binding versus substrate recognition$382,709
R01 · FY2013 · AI · contact PI
UMASS Center for AIDS Research (CFAR)$655,188
P30 · FY2012 · AI · contact PI
Macromolecular Crystallographic HighFlux Home Lab X-ray Diffraction System$530,990
S10 · FY2012 · OD · contact PI
Drug Resistance in HCV NS3/4A - Inhibitor binding versus substrate recognition$407,138
R01 · FY2012 · AI · contact PI
Structural Characterization of APOBECS's Atomic interactions$396,534
P01 · FY2012 · GM · contact PI
Elucidating the Interplay of Protease Substrate Recognition and Drug Resistance$335,890
R01 · FY2012 · GM · contact PI
Elucidating the Interplay of Protease Substrate Recognition and Drug Resistance$51,902
R01 · FY2012 · GM · contact PI
Targeting Ensembles of Drug Resistant HIV-Protease$1,633,675
P01 · FY2011 · GM · contact PI
UMASS Center for AIDS Research (CFAR)$1,310,372
P30 · FY2011 · AI · contact PI
Combatting drug resistance in HIV Protease: A structural Approach$1,282,788
P01 · FY2011 · GM · contact PI
Drug Resistance in HCV NS3/4A - Inhibitor binding versus substrate recognition$407,138
R01 · FY2011 · AI · contact PI
Structural Characterization of APOBECS's Atomic interactions$350,086
P01 · FY2011 · GM · contact PI
Elucidating the Interplay of Protease Substrate Recognition and Drug Resistance$335,890
R01 · FY2011 · GM · contact PI
STRUCTURAL STUDIES OF VIRAL PROTEASES: HIV-1 PROTEASE AND HCV NS3 PROTEASE$21,623
P41 · FY2011 · RR · contact PI
Targeting Ensembles of Drug Resistant HIV-Protease$1,654,373
P01 · FY2010 · GM · contact PI
UMASS Center for AIDS Research (CFAR)$1,323,608
P30 · FY2010 · AI · contact PI
Combatting drug resistance in HIV Protease: A structural Approach$1,297,958
P01 · FY2010 · GM · contact PI
Drug Resistance in HCV NS3/4A - Inhibitor binding versus substrate recognition$411,042
R01 · FY2010 · AI · contact PI
Elucidating the Interplay of Protease Substrate Recognition and Drug Resistance$355,408
R01 · FY2010 · GM · contact PI
Elucidating the Intermolecular Interfaces of APOBEC3's$227,681
R01 · FY2010 · GM · contact PI
UNDERSTANDING DRUG RESISTANCE MECHANISMS OF HIV-1 PROTEASE$6,952
P41 · FY2010 · RR · contact PI
Targeting Ensembles of Drug Resistant HIV-Protease$1,626,662
P01 · FY2009 · GM · contact PI
Combatting drug resistance in HIV Protease: A structural Approach$1,275,133
P01 · FY2009 · GM · contact PI
Targeting Ensembles of Drug Resistant HIV-Protease$600,000
P01 · FY2009 · GM · contact PI
Targeting Drug Resistance in HIV-1 Protease$342,399
R01 · FY2009 · GM · contact PI
Targeting Ensembles of Drug Resistant HIV-Protease$1,583,525
P01 · FY2008 · GM · contact PI
Combatting drug resistance in HIV Protease: A structural Approach$1,240,236
P01 · FY2008 · GM · contact PI
Targeting Drug Resistance in HIV-1 Protease$342,399
R01 · FY2008 · GM · contact PI
Targeting Ensembles of Drug Resistant HIV-Protease$1,772,288
P01 · FY2007 · GM · contact PI
Combatting drug resistance in HIV Protease: A structural Approach$1,342,170
P01 · FY2007 · GM · contact PI
Targeting Drug Resistance in HIV-1 Protease$342,399
R01 · FY2007 · GM · contact PI
HIV-1 Vif: Targeting its molecular interactions$197,234
R21 · FY2007 · AI · contact PI
Targeting ensembles of Drug Resistant HIV Proteases$1,278,108
P01 · FY2006 · GM · contact PI
Targeting Drug Resistance in HIV-1 Protease$344,403
R01 · FY2006 · GM · contact PI
HIV-1 Vif: Targeting its molecular interactions$243,563
R21 · FY2006 · AI · contact PI
Predicting Substrate Specificity in HIV-1 Protease$31,248
R03 · FY2006 · TW · contact PI
Targeting ensembles of Drug Resistant HIV Proteases$1,309,572
P01 · FY2005 · GM
Targeting Drug Resistance in HIV-1 Protease$325,950
R01 · FY2005 · GM
Predicting Substrate Specificity in HIV-1 Protease$32,000
R03 · FY2005 · TW
Targeting ensembles of Drug Resistant HIV Proteases$1,323,553
P01 · FY2004 · GM
Targeting Drug Resistance in HIV-1 Protease$325,950
R01 · FY2004 · GM
HIV-1 Vif: Another Potential Target$238,500
R21 · FY2004 · AI
Predicting Substrate Specificity in HIV-1 Protease$40,320
R03 · FY2004 · TW
Targeting ensembles of Drug Resistant HIV Proteases$1,333,270
P01 · FY2003 · GM
Targeting Drug Resistance in HIV-1 Protease$325,950
R01 · FY2003 · GM
HIV-1 Vif: Another Potential Target$238,500
R21 · FY2003 · AI
Targeting ensembles of Drug Resistant HIV Proteases$2,225,194
P01 · FY2002 · GM
Targeting Drug Resistance in HIV-1 Protease$325,608
R01 · FY2002 · GM
Drug resistance in HIV protease: Utilizing specificity$0
P01 · FY2002 · GM
Targeting Drug Resistance in HIV-1 Protease$321,679
R01 · FY2001 · GM